Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 22 February 2023 to Question 147126 on Bupropion, whether he has made a recent assessment of the adequacy of the availability of bupropion; if he will publish guidance for people using bupropion for ADHD or depression; and if he will take steps to ensure that there is a continued supply.
The Department is aware of a shortage with Bupropion.
We issued comprehensive management guidance to healthcare professionals on this shortage in December 2022. The guidance advises on the management of patients who require this medication for both licensed and off-label indications. Clinicians can advise patients on suitable alternative products, and other management options that can be considered. This includes unlicensed Bupropion 150 milligram modified release tablets which have been sourced.